Rahul Khara - 02 Jan 2026 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Role
Chief Legal Officer
Signature
By: /s/ Rahul Khara
Issuer symbol
IRON
Transactions as of
02 Jan 2026
Net transactions value
-$423,722
Form type
4
Filing time
05 Jan 2026, 20:02:19 UTC
Previous filing
20 Feb 2025
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khara Rahul Chief Legal Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN By: /s/ Rahul Khara 05 Jan 2026 0001951850

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRON Common Stock Options Exercise $87,750 +6,500 +17% $13.50 44,293 02 Jan 2026 Direct F1, F2
transaction IRON Common Stock Sale $27,185 -350 -0.79% $77.67 43,943 02 Jan 2026 Direct F1, F2, F3
transaction IRON Common Stock Sale $392,569 -4,993 -11% $78.62 38,950 02 Jan 2026 Direct F1, F2, F4
transaction IRON Common Stock Sale $91,718 -1,157 -3% $79.27 37,793 02 Jan 2026 Direct F1, F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRON Stock Option (Right to Buy) Options Exercise $0 -6,500 -23% $0.000000 22,270 02 Jan 2026 Common Stock 6,500 $13.50 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.
F2 Includes 210 shares purchased pursuant to the Disc Medicine, Inc. Amended and Restated 2021 Employee Stock Purchase Plan on July 31, 2025.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.09 to $78.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.09 to $79.07, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.10 to $79.49, inclusive.
F6 The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.